Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Cancer Res Treat. 2008 Mar;40(1):11-5. doi: 10.4143/crt.2008.40.1.11. Epub 2008 Mar 31.
To estimate the effect and toxicity of bimonthly low-dose leucovorin (LV) and fluorouracil (5-FU) bolus plus continuous infusion(LV5FU2) with docetaxel combination chemotherapy in patients with inoperable or postoperative relapsed gastric cancer.
Total 27 patients are enrolled in this study. LV 20 mg/m(2) (bolus), 5FU 400 mg/m(2) (bolus), 5-FU 600 mg/m(2) (24-hour continuous infusion) on day 1, 2, 15, and 16, docetaxel 60 mg/m(2) (1-hour infusion) on day 15 every 4 weeks.
Total of 141 cycles were administered and response rate were 36.8% with 2 complete response (10.5%) and 5 partial response (26.3%) in 19 evaluable patients. The median response duration is 8.1 months (95% CI, 4.0 approximately 12.1). The median progression-free survival time is 6.7 months (95% CI, 5.0 approximately 8.5) and the median overall survival time is 11.9 months (95% CI, 4.8 approximately 19.1). The grade 3-4 toxicity of neutropenia (24.8%) and anemia (11.3%), neutropenic fever (2.8%) is observed. The grade 1 toxicity of injection site reaction is observed all patients and the grade 1-2 toxicity of alopecia is observed 60%.
LV5FU2 with docetaxel combination chemotherapy is effective and tolerable in patients with inoperable or postoperative relapsed gastric cancer.
评估每 2 月接受低剂量亚叶酸（LV）和氟尿嘧啶（5-FU）推注联合持续输注（LV5FU2）与多西紫杉醇联合化疗治疗不可切除或术后复发胃癌患者的疗效和毒性。
本研究共纳入 27 例患者。LV 20mg/m2（推注），5-FU 400mg/m2（推注），5-FU 600mg/m2（24 小时持续输注）于第 1、2、15 和 16 天，多西紫杉醇 60mg/m2（1 小时输注）于第 15 天，每 4 周 1 次。
共给予 141 个周期，19 例可评价患者中，2 例（10.5%）完全缓解，5 例（26.3%）部分缓解，总缓解率为 36.8%。中位缓解持续时间为 8.1 个月（95%CI：4.012.1）。中位无进展生存期为 6.7 个月（95%CI：5.08.5），中位总生存期为 11.9 个月（95%CI：4.8~19.1）。中性粒细胞减少症（24.8%）和贫血症（11.3%）、中性粒细胞减少性发热（2.8%）的 3-4 级毒性反应。所有患者均出现 1 级注射部位反应毒性，60%患者出现 1-2 级脱发毒性反应。
LV5FU2 联合多西紫杉醇治疗不可切除或术后复发胃癌患者具有疗效和耐受性。
